Peptide T amide | CAS#113021-67-3 | octapeptide

MedKoo Cat#: 597969 | Name: Peptide T amide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Peptide T amide is an octapeptide segment of HIV envelope gp120; used in AIDS therapy.

Chemical Structure

Peptide T amide

CAS#113021-67-3

Theoretical Analysis

MedKoo Cat#: 597969

Name: Peptide T amide

CAS#: 113021-67-3

Chemical Formula: C31H49N9O13

Exact Mass: 755.3450

Molecular Weight: 755.78

Elemental Analysis: C, 49.27; H, 6.54; N, 16.68; O, 27.52

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Peptide T amide; D-Ala(1)-peptide T amide;

IUPAC/Chemical Name

(S)-N1-((S)-1-(((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-2-((2S,3R)-2-((2S,3R)-2-((S)-2-((S)-2-aminopropanamido)-3-hydroxypropanamido)-3-hydroxybutanamido)-3-hydroxybutanamido)succinamide

InChi Key

LJBGHLZEQUWDLA-FYHOXTKRSA-N

InChi Code

InChI=1S/C31H49N9O13/c1-12(32)26(48)37-20(11-41)29(51)39-24(15(4)44)31(53)40-23(14(3)43)30(52)36-19(10-21(33)46)27(49)35-18(9-16-5-7-17(45)8-6-16)28(50)38-22(13(2)42)25(34)47/h5-8,12-15,18-20,22-24,41-45H,9-11,32H2,1-4H3,(H2,33,46)(H2,34,47)(H,35,49)(H,36,52)(H,37,48)(H,38,50)(H,39,51)(H,40,53)/t12-,13+,14+,15+,18-,19-,20-,22-,23-,24-/m0/s1

SMILES Code

C[C@@H](O)[C@@H](C(N)=O)NC([C@H](CC1=CC=C(O)C=C1)NC([C@H](CC(N)=O)NC([C@H]([C@H](O)C)NC([C@H]([C@H](O)C)NC([C@H](CO)NC([C@H](C)N)=O)=O)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 755.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ruff MR, Polianova M, Yang QE, Leoung GS, Ruscetti FW, Pert CB. Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr HIV Res. 2003 Jan;1(1):51-67. Review. PubMed PMID: 15043212. 2: Su SF, Amidon GL. Investigation into the intestinal metabolism of [D-Ala1] peptide T amide: implication for oral drug delivery. Biochim Biophys Acta. 1995 Aug 17;1245(1):62-8. PubMed PMID: 7654767. 3: Burke TR Jr, Knight M. Counter-current chromatographic purification of [D-Ala]peptide T amide. J Chromatogr. 1987 Dec 18;411:431-5. PubMed PMID: 3443632. 4: Barrera CM, Kastin AJ, Banks WA. D-[Ala1]-peptide T-amide is transported from blood to brain by a saturable system. Brain Res Bull. 1987 Dec;19(6):629-33. PubMed PMID: 3440215. 5: Brenneman DE, Hauser J, Spong CY, Phillips TM, Pert CB, Ruff M. VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. Brain Res. 1999 Aug 14;838(1-2):27-36. PubMed PMID: 10446313. 6: Knight M, Mack GD, Perkins R, Burke TR Jr. Reversed-phase preparative chromatography of [D-Ala1]-peptide T amide. J Chromatogr. 1988 Jul 1;444:345-8. PubMed PMID: 3204139. 7: Goodkin K, Vitiello B, Lyman WD, Asthana D, Atkinson JH, Heseltine PN, Molina R, Zheng W, Khamis I, Wilkie FL, Shapshak P. Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. J Neurovirol. 2006 Jun;12(3):178-89. PubMed PMID: 16877299. 8: Walczak M, Imielska D, Maćkiewicz Z, Kupryszewski G, Dzierzanowska-Madalińska D, Madaliński K. The influence of D-Ala1-peptide T amide, an analogue of HIV glycoprotein 120 fragment, on the CD4--anti CD4 lymphocyte interaction. Arch Immunol Ther Exp (Warsz). 1991;39(1-2):27-31. PubMed PMID: 1804052. 9: Liapi C, Takahashi N, Raynaud F, Evain-Brion D, Anderson WB. Effects of [D-Ala1] peptide T-NH2 and HIV envelope glycoprotein gp120 on cyclic AMP dependent protein kinases in normal and psoriatic human fibroblasts. J Invest Dermatol. 1998 Apr;110(4):332-7. PubMed PMID: 9540970. 10: Raychaudhuri SK, Raychaudhuri SP, Farber EM. Anti-chemotactic activities of peptide-T: a possible mechanism of actions for its therapeutic effects on psoriasis. Int J Immunopharmacol. 1998 Nov;20(11):661-7. PubMed PMID: 9848397. 11: Polianova MT, Ruscetti FW, Pert CB, Ruff MR. Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antiviral Res. 2005 Aug;67(2):83-92. PubMed PMID: 16002156. 12: Pevida M, Lastra A, Meana Á, Hidalgo A, Baamonde A, Menéndez L. The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells. Neuroscience. 2014 Feb 14;259:113-25. doi: 10.1016/j.neuroscience.2013.11.055. Epub 2013 Dec 4. PubMed PMID: 24316469. 13: Saika F, Kiguchi N, Kobayashi Y, Fukazawa Y, Kishioka S. CC-chemokine ligand 4/macrophage inflammatory protein-1β participates in the induction of neuropathic pain after peripheral nerve injury. Eur J Pain. 2012 Oct;16(9):1271-80. doi: 10.1002/j.1532-2149.2012.00146.x. Epub 2012 Apr 24. PubMed PMID: 22528550. 14: Li L, Zhi D, Shen Y, Liu K, Li H, Chen J. Effects of CC-chemokine receptor 5 on ROCK2 and P-MLC2 expression after focal cerebral ischaemia-reperfusion injury in rats. Brain Inj. 2016;30(4):468-73. doi: 10.3109/02699052.2015.1129557. Epub 2016 Mar 16. PubMed PMID: 26983670.